Michael E. Selsted, MD, PhD

Professor of Pathology

Seth MacFarlane Professor of Immunopathology

Image of Michael E. Selsted, MD, PhD
Is this your profile? Click to edit

Overview

Dr. Selsted is a board certified pathologist, physician scientist, and administrator. His academic career includes appointments as Professor (1989-2009) and Chair of Pathology at UC Irvine School of Medicine (2000 – 2009) and Professor and Chair of Pathology in the Keck School of Medicine (2009 – 2024). Dr. Selsted leads a multidisciplinary research program focused on mammalian host defense, innate immunity, and inflammation. This focus led to the discovery and characterization of α-, β-, and θ-defensins, microbicidal and immunomodulatory peptides expressed in myeloid and epithelial cells of vertebrates. These investigations, continuously funded by NIH since 1986, have resulted in more than 50 US and foreign patents, as well as clinical translation of a θ-defensin for treatment of rheumatoid arthritis. Ongoing studies seek to elucidate the immunoregulatory mechanisms of these peptides, design and application of novel analogs, and application of θ-defensin-inspired macrocyclic peptides in models of autoimmune diseases, cancer, and infections caused by MDR bacterial and fungal pathogens.

Research Funding

  • Host defense-stimulating macrocyclic peptides for treatment of MDR bacterial infections
    NIH · R01AI125141 · May 1, 2016 – Apr 30, 2021 · Role: Principal Investigator
  • Regulation of Mucosal Immunity by Pro- and Anti-inflammatory Salivary Defensins
    NIH · R01DE021341 · Aug 12, 2010 – May 31, 2015 · Role: Principal Investigator
  • Physiologic Peptide Cyclization in Myeloid Cells
    NIH · R01AI058129 · Jun 1, 2004 – May 31, 2009 · Role: Principal Investigator
  • Molecular Ontogeny of Oral Mucosal Resistance to SIV
    NIH · R01DE015517 · Dec 15, 2003 – Nov 30, 2009 · Role: Principal Investigator
  • DRUG DISCOVERY FOR TREATMENT OF CRYPTOCOCCAL DISEASE
    NIH · U01AI031696 · Aug 1, 1991 – Jul 31, 1995 · Role: Principal Investigator
  • MOLECULAR ASPECTS OF LEUKOCYTE ANTIMICROBIAL PEPTIDES
    NIH · R37AI022931 · Jul 1, 1989 – Mar 31, 2012 · Role: Principal Investigator
  • Molecular Aspects of Leukocyte Antimicrobial Peptides
    NIH · R01AI022931 · Jul 1, 1986 – May 31, 2019 · Role: Principal Investigator

Publications

  • Differential Susceptibility of Bacteria to Mouse Paneth Cell α-Defensins under Anaerobic Conditions. Antibiotics (Basel). 2014; 3(4):493-508.. View in PubMed
  • Microbicidal effects of α- and θ-defensins against antibiotic-resistant Staphylococcus aureus and Pseudomonas aeruginosa. Innate Immun. 2015 Jan; 21(1):17-29.. View in PubMed
  • Rhesus macaque theta defensins suppress inflammatory cytokines and enhance survival in mouse models of bacteremic sepsis. PLoS One. 2012; 7(12):e51337.. View in PubMed
  • Immunology. HD6 defensin nanonets. Science. 2012 Jul 27; 337(6093):420-1.. View in PubMed
  • High fidelity processing and activation of the human α-defensin HNP1 precursor by neutrophil elastase and proteinase 3. PLoS One. 2012; 7(3):e32469.. View in PubMed
  • RTD-1mimic containing γPNA scaffold exhibits broad-spectrum antibacterial activities. J Am Chem Soc. 2012 Mar 07; 134(9):4041-4.. View in PubMed
  • Alternative luminal activation mechanisms for paneth cell α-defensins. J Biol Chem. 2012 Mar 30; 287(14):11205-12.. View in PubMed
  • Cycloquest: identification of cyclopeptides via database search of their mass spectra against genome databases. J Proteome Res. 2011 Oct 07; 10(10):4505-12.. View in PubMed
  • Criterion for amino acid composition of defensins and antimicrobial peptides based on geometry of membrane destabilization. J Am Chem Soc. 2011 May 04; 133(17):6720-7.. View in PubMed
  • Rhesus macaque θ-defensin isoforms: expression, antimicrobial activities, and demonstration of a prominent role in neutrophil granule microbicidal activities. J Leukoc Biol. 2011 Feb; 89(2):283-90.. View in PubMed